Ignite Creation Date:
2025-12-25 @ 5:03 AM
Ignite Modification Date:
2025-12-26 @ 4:06 AM
Study NCT ID:
NCT01618318
Status:
COMPLETED
Last Update Posted:
2013-12-05
First Post:
2012-06-08
Is NOT Gene Therapy:
False
Has Adverse Events:
False
Brief Title:
Glasgow Asthma and Allergy Study
Sponsor:
Organization:
Raw JSON
{'hasResults': False, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-12-24'}, 'conditionBrowseModule': {'meshes': [{'id': 'D001249', 'term': 'Asthma'}, {'id': 'D006967', 'term': 'Hypersensitivity'}, {'id': 'D004194', 'term': 'Disease'}], 'ancestors': [{'id': 'D001982', 'term': 'Bronchial Diseases'}, {'id': 'D012140', 'term': 'Respiratory Tract Diseases'}, {'id': 'D008173', 'term': 'Lung Diseases, Obstructive'}, {'id': 'D008171', 'term': 'Lung Diseases'}, {'id': 'D012130', 'term': 'Respiratory Hypersensitivity'}, {'id': 'D006969', 'term': 'Hypersensitivity, Immediate'}, {'id': 'D007154', 'term': 'Immune System Diseases'}, {'id': 'D010335', 'term': 'Pathologic Processes'}, {'id': 'D013568', 'term': 'Pathological Conditions, Signs and Symptoms'}]}}, 'protocolSection': {'designModule': {'studyType': 'OBSERVATIONAL', 'designInfo': {'timePerspective': 'CROSS_SECTIONAL', 'observationalModel': 'COHORT'}, 'enrollmentInfo': {'type': 'ACTUAL', 'count': 105}}, 'statusModule': {'overallStatus': 'COMPLETED', 'startDateStruct': {'date': '2012-06'}, 'expandedAccessInfo': {'hasExpandedAccess': False}, 'statusVerifiedDate': '2013-12', 'completionDateStruct': {'date': '2013-10', 'type': 'ACTUAL'}, 'lastUpdateSubmitDate': '2013-12-04', 'studyFirstSubmitDate': '2012-06-08', 'studyFirstSubmitQcDate': '2012-06-12', 'lastUpdatePostDateStruct': {'date': '2013-12-05', 'type': 'ESTIMATED'}, 'studyFirstPostDateStruct': {'date': '2012-06-13', 'type': 'ESTIMATED'}, 'primaryCompletionDateStruct': {'date': '2013-10', 'type': 'ACTUAL'}}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'Serum periostin level', 'timeFrame': '1 day', 'description': 'This is a cross sectional study. Participants will be assessed and tests conducted at a single visit'}], 'secondaryOutcomes': [{'measure': 'skin prick test', 'timeFrame': '1 day'}, {'measure': 'Serum total IgE', 'timeFrame': '1 day'}, {'measure': 'Blood eosinophil count', 'timeFrame': '1 day'}, {'measure': 'Blood neutrophil count', 'timeFrame': '1 day'}, {'measure': 'Blood CD4 cells that are positive for CRTh2', 'timeFrame': '1 day'}, {'measure': 'Blood eosinophils expressing CRTh2', 'timeFrame': '1 day'}, {'measure': 'Spirometry', 'timeFrame': '1 day'}]}, 'oversightModule': {'oversightHasDmc': False}, 'conditionsModule': {'keywords': ['Asthma', 'Allergy', 'Diagnosis', 'Correlation study'], 'conditions': ['Asthma', 'Allergy']}, 'descriptionModule': {'briefSummary': 'In the past, doctors separated people with asthma into two groups, those with "allergic asthma" (about 2/3rds of people) and those with "non-allergic asthma". These labels are not much used now as the treatments for all people with asthma don\'t depend on this classification. However, new treatments for asthma may become available and the classification may again become important. It could be useful for clinicians to know how to identify which patients are likely to benefit from particular treatments.\n\nAdditionally, some new blood tests are becoming available and some of these might help to categorise the type of asthma people have. What the study hopes to do is to identify patient features which make a diagnosis of "allergic asthma" more likely and to see which new blood tests are most likely to be helpful in confirming this diagnosis.'}, 'eligibilityModule': {'sex': 'ALL', 'stdAges': ['ADULT', 'OLDER_ADULT'], 'minimumAge': '18 Years', 'samplingMethod': 'NON_PROBABILITY_SAMPLE', 'studyPopulation': 'People with asthma, non smoker, aged 18 and over.', 'healthyVolunteers': False, 'eligibilityCriteria': 'Inclusion Criteria:\n\n* Male and female patients aged 18 years old and over with a diagnosis of asthma and having received at least two prescriptions for any asthma medication in the last 12 months, who have signed an informed consent form prior to initiation of any study-related procedure\n\nExclusion Criteria:\n\n* under 18 years\n* current smokers\n* unwilling or unable to give informed consent\n* a clinical diagnosis of COPD\n* a history of anaphylaxis (skin prick test)\n* participated in any clinical study in the last 12 months'}, 'identificationModule': {'nctId': 'NCT01618318', 'acronym': 'GLAAS', 'briefTitle': 'Glasgow Asthma and Allergy Study', 'organization': {'class': 'INDUSTRY', 'fullName': 'National Services for Health Improvement Ltd'}, 'officialTitle': 'Cross Sectional Study to Evaluate and Associate Clinical and Laboratory Features of People With Allergic and Non-allergic Asthma', 'orgStudyIdInfo': {'id': '12/WS/0049'}}, 'armsInterventionsModule': {'armGroups': [{'label': 'General asthma population', 'description': 'People with asthma, aged 18 years and over, non smoker, all severities of disease, regardless of treatment, broad inclusion and few exclusion criteria.'}]}, 'contactsLocationsModule': {'locations': [{'zip': 'DA1 5GA', 'city': 'Dartford', 'state': 'Kent', 'country': 'United Kingdom', 'facility': 'NSHI Ltd', 'geoPoint': {'lat': 51.44657, 'lon': 0.21423}}], 'overallOfficials': [{'name': 'John A Haughney, MB ChB', 'role': 'PRINCIPAL_INVESTIGATOR', 'affiliation': 'NSHI Ltd'}]}, 'sponsorCollaboratorsModule': {'leadSponsor': {'name': 'National Services for Health Improvement Ltd', 'class': 'INDUSTRY'}, 'collaborators': [{'name': 'Merck Sharp & Dohme LLC', 'class': 'INDUSTRY'}], 'responsibleParty': {'type': 'SPONSOR'}}}}